Smoked cannabis for spasticity in multiple sclerosis: A randomized, placebo-controlled trial

CMAJ. Canadian Medical Association Journal

Volumn 184, Issue 10, 2012, Pages 1143-1150

  Corey Bloom, Jody ^a   Wolfson, Tanya ^b   Gamst, Anthony ^b   Jin, Shelia ^b   Marcotte, Thomas D ^c,d   Bentley, Heather ^c,d   Gouaux, Ben ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d University of California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; PLACEBO;

ABNORMAL SENSATION; ADULT; AGED; ARTICLE; ASHWORTH SCALE; BRADYCARDIA; CLINICAL ARTICLE; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG EFFECT; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; MALE; MULTIPLE SCLEROSIS; NAUSEA; PACED AUDITORY SERIAL ADDITION TEST; PAIN ASSESSMENT; PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SPASTICITY; TACHYCARDIA; THROAT IRRITATION; VISUAL ANALOG SCALE;

EID: 84863645307     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.110837     Document Type: Article

References (29)

1. Watson SJ, Benson JA Jr, Joy JE. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry 2000;57:547-52.
2. Pryce G, Baker D. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol 2007;150:519-25.
3. Brooks JW, Pryce G, Bisogno T, et al. Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. Eur J Pharmacol 2002; 439: 83-92.
4. Smith PF. New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids. Ther Clin Risk Manag 2010;6:59-63.
5. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67:206-7.
6. Foltin RW, Ficshman MW, Nellis MJ, et al. Marijuana effects and behavioral contingencies. NIDA Res Monogr 1986;67: 355-61.
7. Mehmedic Z, Chandra S, Slade D, et al. Potency trends of Delta9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 2010;55:1209-17.
8. Katz RT, Rovai GP, Brait C, et al. Objective quantification of spastic hypertonia: correlation with clinical findings. Arch Phys Med Rehabil 1992;73:339-47.
9. Farrar JT, Troxel AB, Stott C, et al. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008;30:974-85.
10. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-26.
11. Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-41.
12. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005; 76: 1664-9.
13. Collin C, Davies P, Mutiboko IK, et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14:290-6.
14. Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010;32:451-9.
15. Vakhapova V, Auriel E, Karni A. Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety. Clin Neuropharmacol 2010;33:151-4.
16. Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989;320:1517-21.
17. Centonze D, Mori F, Koch G, et al. Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis. Neurol Sci 2009;30:531-4.
18. Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-9.
19. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007;68:515-21.
20. Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009;34:672-80.
21. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010; 182:E694-701.
22. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004;10:417-24.
23. Aragona M, Onesti E, Tomassini V, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol 2009;32:41-7.
24. Heaton RK, et al. Revised comprehensive norms for an expanded Halstead-Reitan battery: demographically adjusted neuropsychological norms for African American and Caucasian adults. Lutz (FL): Psychological Assessment Resources; 2004.
25. Shah J, Wesnes KA, Kovelesky RA, et al. Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers. Clin Ther 2006; 28: 1308-17.
26. Ghaffar O, Feinstein A. Multiple sclerosis and cannabis: a cognitive and psychiatric study. Neurology 2008;71:164-9.
27. Honarmand K, Tierney MC, O'Connor P, et al. Effects of cannabis on cognitive function in patients with multiple sclerosis. Neurology 2011;76:1153-60.
28. Arnett PA. Cannabis bliss? Perhaps not? Neurology 2008; 71: 160-1.
29. Messinis L, Papathanasopoulos P. Multiple sclerosis and cannabis: a cognitive and psychiatric study. Neurology 2009; 72: 100-1, author reply 101.